UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): March 7, 2018
Intiva BioPharma Inc.
(Exact Name Of Registrant As Specified In Its Charter)
Commission File No.: 0-55320
Delaware | 26-2049376 | |
(State of Incorporation) | (I.R.S. Employer Identification No.) | |
4340 E Kentucky Ave, Suite 206, Glendale, CO | 80246 | |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s Telephone Number, including area code: (973) 370-3768
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective March 7, 2018, Jeffrey Friedland resigned as the registrant’s Chief Executive Officer and a director. Alain Bankier, the registrant’s chief strategy officer and a member of the board of directors, has been appointed to serve as the interim chief executive officer.
2 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/: Richard Greenberg | |
Richard Greenberg, Executive Vice President March 8, 2018 |
3 |